ELI LILLY AND COMPANY Effective Tax Rate
ELI LILLY AND COMPANY (LLY) reported Effective Tax Rate of 23.30% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-08-05
- ELI LILLY AND COMPANY effective income tax rate reconciliation, percent for the quarter ending 2026-06-30 was 23.30%, a 41.21% increase year-over-year.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, percent for the quarter ending 2026-03-31 was 16.40%, a 18.81% decline year-over-year.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, percent for the quarter ending 2025-09-30 was 22.80%, a 41.39% decline year-over-year.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, percent for the quarter ending 2025-06-30 was 16.50%, a 5.77% increase year-over-year.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, percent for fiscal 2025 was 19.80%, a 20.00% increase from fiscal 2024.
- ELI LILLY AND COMPANY effective income tax rate reconciliation, percent for fiscal 2024 was 16.50%.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 6 month as first filed | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 23.30% 10-Q · filed 2026-08-05 | 19.90% 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 16.40% 10-Q · filed 2026-04-30 | ||||
| 2025-12-31 | 19.80% 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | 22.80% 10-Q · filed 2025-10-30 | 19.80% 10-Q · filed 2025-10-30 | |||
| 2025-06-30 | 16.50% 10-Q · filed 2026-08-05 | 17.70% 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | 20.20% 10-Q · filed 2026-04-30 | ||||
| 2024-12-31 | 16.50% 10-K · filed 2026-02-12 | ||||
| 2024-09-30 | 38.90% 10-Q · filed 2025-10-30 | 19.10% 10-Q · filed 2025-10-30 | |||
| 2024-06-30 | 15.60% 10-Q · filed 2025-08-07 | 13.90% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 11.60% 10-Q · filed 2025-05-01 | ||||
| 2023-09-30 | 113.40% 10-Q · filed 2024-10-30 | 24.60% 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | 15.60% 10-Q · filed 2024-08-08 | 14.10% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 12.10% 10-Q · filed 2024-04-30 | ||||
| 2022-09-30 | 7.30% 10-Q · filed 2023-11-02 | 8.60% 10-Q · filed 2023-11-02 | |||
| 2022-06-30 | 12.70% 10-Q · filed 2023-08-08 | 9.20% 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 7.30% 10-Q · filed 2023-04-27 | ||||
| 2021-09-30 | 10.90% 10-Q · filed 2022-11-01 | 10.70% 10-Q · filed 2022-11-01 | |||
| 2021-06-30 | 12.80% 10-Q · filed 2022-08-04 | 10.60% 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 8.20% 10-Q · filed 2022-04-29 | ||||
| 2020-09-30 | 15.90% 10-Q · filed 2021-10-27 | 14.40% 10-Q · filed 2021-10-27 | |||
| 2020-06-30 | 14.10% 10-Q · filed 2021-08-03 | 13.70% 10-Q · filed 2021-08-03 | |||
| 2020-03-31 | 13.30% 10-Q · filed 2021-04-30 | ||||
| 2019-09-30 | 10.80% 10-Q · filed 2020-10-28 | 12.80% 10-Q · filed 2020-10-28 | |||
| 2019-06-30 | 9.50% 10-Q · filed 2020-07-31 | 14.10% 10-Q · filed 2020-07-31 | |||
| 2019-03-31 | 23.30% 10-Q · filed 2020-05-01 | ||||
| 2018-09-30 | 18.50% 10-Q · filed 2019-10-25 | 26.20% 10-Q · filed 2019-10-25 | |||
| 2018-06-30 | 33.50% 10-Q · filed 2019-08-02 | 33.80% 10-Q · filed 2018-07-25 | |||
| 2018-03-31 | 14.50% 10-Q · filed 2019-05-02 | ||||
| 2017-09-30 | 6.10% 10-Q · filed 2018-11-06 | 24.10% 10-Q · filed 2018-11-06 | |||
| 2017-06-30 | 32.10% 10-Q · filed 2018-07-25 | ||||
| 2016-09-30 | 19.90% 10-Q · filed 2017-10-27 | 20.80% 10-Q · filed 2017-10-27 | |||
| 2016-06-30 | 21.40% 10-Q · filed 2017-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |